Meeting NewsVideo

VIDEO: Potassium-binding agents help enable tolerance of HF medications

CHICAGO — In this video exclusive, Cardiology Today Editorial Board Member Ileana L. Piña, MD, MPH, discussed her Cardiometabolic Health Congress workshop on the role of potassium-binding agents in optimizing guideline-directed therapy for HF.

Piña, professor of medicine at Wayne State University, clinical professor of medicine at Central Michigan University and director of CVD research and academic affairs and regional and national director of HF at Detroit Medical Center, said the workshop focused on complications that prevent some clinicians from starting patients on guideline-directed renin-angiotensin-aldosterone system inhibitors for treatment of HF, and how potassium-binding agents can alleviate these.

Watch the video for more.

CHICAGO — In this video exclusive, Cardiology Today Editorial Board Member Ileana L. Piña, MD, MPH, discussed her Cardiometabolic Health Congress workshop on the role of potassium-binding agents in optimizing guideline-directed therapy for HF.

Piña, professor of medicine at Wayne State University, clinical professor of medicine at Central Michigan University and director of CVD research and academic affairs and regional and national director of HF at Detroit Medical Center, said the workshop focused on complications that prevent some clinicians from starting patients on guideline-directed renin-angiotensin-aldosterone system inhibitors for treatment of HF, and how potassium-binding agents can alleviate these.

Watch the video for more.

    See more from Cardiometabolic Health Congress